CTRI/2018/06/014520尚未招募3 期
Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants - IMPAACT2010
IH DAIDS0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 HIV infected pregnant women initiating Antiretroviral medication at 14-28 weeks of gestation
- •2 18 years of age and ready to give informed consent
- •3 no evidence of multiple gestation or fetal anomalies
排除标准
- •1Mother is currently incarcerated or involuntarily confined in a medical facility
- •2A psychoactive medication for treatment of a psychiatric illness
- •3Treatment for active tuberculosis
- •4Treatment for active hepatitis C infection
研究者
相似试验
进行中（未招募）
不适用
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential Hypertension - NDMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionhypertensionEUCTR2006-005556-32-ITMENARINI RICERCHE S.P.A.1,400
进行中（未招募）
不适用
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential HypertensioEUCTR2006-005556-32-DKMenarini Ricerche S.p.A.1,400
进行中（未招募）
不适用
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential HypertensioEUCTR2006-005556-32-CZMenarini Ricerche S.p.A.1,400
进行中（未招募）
不适用
Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential HypertensioEUCTR2006-005556-32-DEMenarini Ricerche S.p.A.1,400
已完成
3 期
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their InfantsHIV InfectionsNCT03048422National Institute of Allergy and Infectious Diseases (NIAID)643